Summary:
- Azvudine is a new antiviral drug that has been approved for the treatment of COVID-19 in China. It works by inhibiting the replication of the SARS-CoV-2 virus, which causes COVID-19.
- Clinical trials have shown that Azvudine can effectively reduce the viral load and improve the symptoms of COVID-19 patients, especially those with mild to moderate cases.
- The approval of Azvudine is a significant development in the ongoing efforts to combat the COVID-19 pandemic, as it provides an additional treatment option for those affected by the virus.